NOTCH1 and neoplasm: It thus opens a new avenue to target TME by either reprograming and converting CAF from ‘tumor promoters’ to ‘tumor suppressors’ through therapeutic activation of Notch1 pathway or directly exploiting Notch downstream mediator(s), i.e. WISP1 [11].